Study Details
Rozanolixizumab: A Study Drug for People with Myelin Oligodendrocyte Glycoprotein (MOG) antibody associated disease (MOG-AD)
(IRB#: IRB_00148171)
Myelin Oligodendrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD) may inflame a persons central nervous system severely affecting nerves in the eyes, brain, and spinal cord. Rozanolixizumab is a study drug to help people with MOG-AD. Research is needed to learn the safety and effectiveness of the study drug. The information we gain may aid future patients.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes
IRB#: IRB_00148171
PI: Stacey Clardy
Department: NEUROLOGY
Approval Date: 2022-10-05 06:00:00
Study Categories: Brain Health Studies, Studies Related to the Eye
Specialties: Neurology, Ophthalmology